ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference

ADDISON, Texas, Dec. 9  /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE Alternext: ULU) announced today that a presentation on Altrazeal(TM) Transforming Powder Dressing will be made at the prestigious 10th Annual Wound Healing Science and Industry Conference to be held December 10-13, 2009 in St Thomas, U.S. Virgin Islands. The presentation will include research on advanced applications of Altrazeal(TM) related to the development of future products in drug delivery and tissue engineering. This conference is organized as a collaborative series of symposia and poster presentations with many of the top scientists and clinicians in the field of wound care discussing advanced research and treatments.  Conference details and the program can be found at http://www.stthomaswoundhealing.com/.

John V. St. John, PhD, Vice President of Research and Development for ULURU Inc., is part of a limited number of industry scientists who have been invited to make a podium presentation. The presentation to be made by Dr. St. John will detail the physical and chemical nature of Altrazeal(TM) and highlight the research performed at ULURU Inc. on the development of advanced products allowing controlled release of growth factors.  Commenting on the meeting, Peter Sheehan, MD, a conference organizer, stated:  "The meeting is a gathering of elite scientists and industry leaders to exchange ideas on new directions in the field of Wound Healing. It's really become the Davos of Wound Healing."

Renaat Van den Hooff, President and CEO of ULURU Inc., commented: "It is very prestigious for our company that Dr. St. John has been invited to participate in this leading symposium. I believe it is a tribute to the novelty of Altrazeal(TM) and the Nanoflex technology, and a recognition that Altrazeal(TM) has the potential to impact the way wounds will be more effectively treated in the future.  We remain committed to the development of advanced therapies in wound healing and to the integration of the latest scientific advances into our future product development programs."

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex(TM) Aggregate technology and OraDisc(TM) transmucosal delivery system. For further information about ULURU Inc., please visit our website at http://www.uluruinc.com/.  For further information about Altrazeal(TM), please visit http://www.altrazeal.com/.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to the effectiveness in wound healing of Altrazeal(TM).  These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and other reports filed by us with the Securities and Exchange Commission.

  Contact: Company
  ----------------
  Renaat Van den Hooff
  President & CEO
  Terry K. Wallberg
  Vice President & CFO
  [phone]


DATASOURCE: ULURU Inc.



CONTACT:  Renaat Van den Hooff, President & CEO, or Terry K. Wallberg,

Vice President & CFO, both of ULURU Inc., [phone]



Web Site:  http://www.uluruinc.com/

http://www.altrazeal.com/ 

Copyright